Get involved

Doxebo is a liposomal formulation jointly invented by the israeli and hungarian applicants. It reduces the risk of serious, occasionally lethal adverse effect of doxil and other similar nano-drugs. In this application we propose preclinical studies necessary for regulatory approval of doxebo.

The mission of the consortium is to utilize state-of-the-art pharmaceutical approaches and develop tnf-alpha-binding protein-imprinted polymers for the specific elimination of tnf-alpha from the gastrointestinal tract hence improving the therapy of currently untreatable crohn's disease.